What separates the two compounds?
Because these two are sold together as a pair, they are often described as though one were a stronger or longer-acting version of the other. They are not related that way at all. They are two separate keys fitting two separate locks that happen to open onto the same room.
How do they compare point by point?
HUMAN AND PRECLINICAL — SEPARATE STUDIES
| CJC-1295 with DAC | Ipamorelin | |
|---|---|---|
| Compound class | GHRH(1-29) analogue with albumin-binding group | Five-amino-acid ghrelin receptor agonist |
| Receptor | GHRH receptor on pituitary somatotrophs | GHS-R1a, the ghrelin receptor |
| Duration | Estimated half-life 5.8 to 8.1 days | Short-acting |
| Best human data | Randomised placebo-controlled ascending-dose studies in healthy adults | Phase 2 randomised placebo-controlled trial in postoperative gastrointestinal recovery, 117 enrolled |
| Measured endocrine effect | GH increased two- to ten-fold for at least six days; IGF-I increased 1.5- to 3-fold for nine to eleven days | GH release with EC50 of 1.3 nM in rat pituitary cells; no significant ACTH or cortisol rise |
| Pulsatility | Pulse frequency and magnitude unchanged; basal GH rose 7.5-fold | Not characterised in comparable human studies |
| Regulatory status | Not approved; development discontinued | Not approved; development did not reach approval |
Why does duration change the whole comparison?
Half-life is the time it takes for the concentration of a substance in the body to fall by half. A compound with a half-life measured in days behaves in a fundamentally different way from one measured in minutes, and not simply by lasting longer.
A short-acting compound produces a brief pulse of signal that rises and clears, which broadly resembles how these hormones are released naturally. A compound that persists for days produces continuous receptor exposure. The obvious concern with continuous exposure is that receptors and feedback loops adapt to it, which is why the pulsatility study of CJC-1295 mattered: it specifically checked whether the natural pulse pattern survived a week of continuous stimulation. It reported that pulse frequency and magnitude were preserved while basal levels rose sharply. [3]
For ipamorelin, no equivalent long-duration human pulsatility study was identifiable. Its short action means it is generally studied as a discrete stimulus rather than as continuous exposure.
How strong is each evidence base?
EVIDENCE-LEVEL ASSESSMENT
Both evidence bases are thinner than the confident marketing around them suggests, but they are thin in different ways.
CJC-1295 has two peer-reviewed human studies in healthy volunteers, both from 2006, both measuring endocrine markers rather than clinical outcomes. Growth hormone and IGF-I are intermediate markers: they describe what the endocrine system did, not whether anything of clinical value followed. The compound's only clinical-outcome trial, in HIV-associated lipodystrophy, was halted after a participant death, with the sponsor describing the relationship to study drug as inconclusive, and development did not continue. [1][3]
Ipamorelin has stronger preclinical pharmacology, with dose-response data across cells, rats and swine, and one published phase 2 clinical trial with a genuine clinical endpoint, time to tolerate a solid meal after bowel surgery. That trial reported 25.3 hours against 32.6 hours on placebo in 117 enrolled participants. A larger 320-participant dose-finding trial completed but no peer-reviewed publication of its results was identifiable, which is itself informative: unpublished completed trials are a known source of bias in any literature. [4][5][6]
Neither compound has published evidence of a body-composition, performance or longevity outcome in humans. Claims of that kind circulate widely and are not supported by any primary study identified here.
Should they be considered as a pair at all?
Mechanistically, pairing a GHRH-pathway compound with a ghrelin-pathway compound has a real rationale. Studies from the 1990s using GHRH with GHRP-6 found the combination produced growth hormone release well beyond the sum of either alone, and follow-up work showed the ghrelin-pathway compound depends partly on intact GHRH signalling to produce its full effect. That is a coherent explanation for why two pathways might amplify each other. [7]
What does not exist is any study of this particular pair. No published human study and no registered clinical trial of CJC-1295 with ipamorelin was identifiable. The accurate position is that the pairing rests on analogy to related molecules, and that the specific combination has never been tested in a controlled setting.
For the full mechanistic detail on both pathways, see CJC-1295 and ipamorelin mechanism.
For the nomenclature problem in detail, see CJC-1295 with DAC versus without DAC.
Frequently Asked Questions
Which is stronger, CJC-1295 or ipamorelin?
The question cannot be answered from evidence. No head-to-head study exists, and the two compounds were studied with different endpoints in different populations. CJC-1295 lasts far longer, with an estimated half-life of 5.8 to 8.1 days against ipamorelin's short duration.
Do they act on the same receptor?
No. CJC-1295 acts on the GHRH receptor and ipamorelin on GHS-R1a, the ghrelin receptor. Both receptors sit on the same pituitary cells, which is the basis for the theory that they might amplify each other.
Is the combination supported by evidence?
No published human study or registered clinical trial of the two together was identifiable. Synergy has been shown between GHRH and GHRP-6, which are different molecules, so the pairing rests on analogy rather than direct evidence.
Are either of them approved medicines?
No. Neither compound is approved by any regulator for any indication, and both fall within the World Anti-Doping Agency's S2 prohibited category. Origen supplies them as research material for laboratory use only.
